Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Refametinib + Gemcitabine in Pancreatic Cancer
NCT01251640Phase 2Completed
- Sponsor
- Bayer
- Start
- Jan 2011
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of refametinib in pancreatic adenocarcinoma (PDAC), sponsored by Bayer. Started Jan 2011; status: completed.
02
Drugs
refametinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01251640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01251640.